Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

Phase 2

Terminated

Conditions: Relapsed Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions: Drug: Loncastuximab Tesirine
Drug: Idelalisib

Registration Number: NCT04699461

Lead Sponsor: ADC Therapeutics S.A.

Brief Summary: This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 6

Inclusion Criteria

Written informed consent must be obtained prior to any study procedures.
Male or female participants aged 18 years or older, with pathologic diagnosis of follicular lymphoma (FL) (Grade 1, 2, 3A) in the most recent tumor biopsy.
Relapsed or refractory disease following two or more treatment regimens, at least one of which must have contained an anti-CD20 therapy.
Participants who have received previous CD19-directed therapy must have a biopsy which shows CD19 expression after completion of the CD19-directed therapy.
Measurable disease as defined by the 2014 Lugano Classification as assessed by positron emission tomography - computed tomography (PET-CT) or, if not Fluorodeoxyglucose (FDG) avid, CT or magnetic resonance imaging (MRI).
Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block (or minimum 10 freshly cut unstained slides if block is not available). Note: Any biopsy since initial diagnosis is acceptable, but if several samples are available, the most recent sample is preferred.
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
Adequate organ function as defined by screening laboratory values within the following parameters:
1. Absolute neutrophil count (ANC) ≥1.0 × 10^3/μL (off growth factors at least 72 hours),
2. Platelet count ≥75 × 10^3/μL without transfusion in the past 2 weeks,
3. Alanine aminotransferase, AST, and GGT ≤2.5 × the upper limit of normal (ULN),
4. Total bilirubin ≤1.5 × ULN (participants with known Gilbert's syndrome may have a total bilirubin up to ≤3 × ULN),
5. Calculated creatinine clearance ≥30 mL/min by the Cockcroft and Gault equation. Note: A laboratory assessment may be repeated a maximum of two times during the Screening period to confirm eligibility
Women of childbearing potential (WOCBP)(1) must agree to use a highly effective method(2) of contraception from the time of giving informed consent until at least 9 months after the last dose of study treatment. Men with female partners who are of childbearing potential must agree to use a condom when sexually active or practice total abstinence from the time of giving informed consent until at least 6 months after the participant receives his last dose of study treatment.
1. WOCBP are defined as sexually mature women who have not undergone bilateral tubal ligation, bilateral oophorectomy, or hysterectomy; or who have not been postmenopausal. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
2. Highly effective forms of birth control are methods that achieve a failure rate of less than 1% per year when used consistently and correctly. Highly effective forms of birth control include hormonal contraceptives associated with inhibition of ovulation (oral, injectable, patch, intrauterine devices), male partner sterilization, or total abstinence from heterosexual intercourse, when this is the preferred and usual lifestyle of the participant.

Note: The double-barrier method (e.g., synthetic condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel), periodic abstinence (such as calendar, symptothermal, post ovulation), withdrawal (coitus interruptus), lactational amenorrhea method, and spermicide-only are not acceptable as highly effective methods of contraception.

Exclusion Criteria

Previous treatment with loncastuximab tesirine.
Previous treatment with idelalisib.
History of hypersensitivity to any of the excipients of loncastuximab tesirine or idelalisib.
Follicular lymphoma which has transformed to diffuse large B-cell lymphoma (DLBCL) or other aggressive lymphomas.
Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor, inducer, or sensitive substrate.
History of or ongoing drug-induced pneumonitis.
History of or ongoing inflammatory bowel disease.
Any condition that could interfere with the absorption or metabolism of idelalisib including malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.
Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's medical monitor and Investigator agree and document should not be exclusionary.
Autologous transplant within 30 days prior to start of study treatment (C1D1).
Allogenic transplant within 60 days prior to start of study treatment (C1D1).
Active graft-versus-host disease.
Post-transplantation lymphoproliferative disorders.
Human immunodeficiency virus (HIV) seropositive with any of the following:
1. CD4+ T-cell counts <350 cells/μL.
2. Acquired immuno-deficiency syndrome (AIDS)-defining opportunistic infection within 12 months prior to screening.
3. Not on anti-retroviral therapy, or on anti-retroviral therapy for < 4 weeks at the time of screening.
4. HIV viral load ≥400 copies/mL.
Serologic evidence of chronic hepatitis B infection and unable or unwilling to receive standard prophylactic anti-viral therapy or with detectable hepatitis B virus (HBV) viral load.
Serologic evidence of hepatitis C infection without completion of curative treatment or with detectable hepatitis C virus (HCV) viral load.
History of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Lymphoma with active central nervous system involvement, including leptomeningeal disease.
Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath).
Breastfeeding or pregnant.
Significant medical comorbidities, including but not limited to, uncontrolled hypertension (BP ≥160/100 mm Hg repeatedly), unstable angina, congestive heart failure (greater than New York Heart Association class II), electrocardiographic evidence of acute ischemia, coronary angioplasty or myocardial infarction within 6 months prior to screening, uncontrolled atrial or ventricular cardiac arrhythmia, poorly controlled diabetes, or severe chronic pulmonary disease.
Any Grade ≥3 active infection which requires IV antibiotics, IV antiviral, or IV antifungal treatment.
Major surgery, radiotherapy, chemotherapy or other anti-neoplastic therapy within 14 days prior to start of study treatment (C1D1), except shorter if approved by the Sponsor.
Use of any other experimental medication within 30 days prior to start of study treatment (C1D1).
Live vaccine administration within 4 weeks prior to Cycle(C) 1 Day (D) 1.
Failure to recover to ≤ Grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) from acute non-hematologic toxicity (except ≤Grade 2 neuropathy or alopecia) due to previous therapy prior to screening.
Any other significant medical illness, abnormality, or condition that would, in the Investigator's judgment, make the participant inappropriate for study participation or put the participant at risk.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Loncastuximab Tesirine	Loncastuximab Tesirine	Participants will be administered loncastuximab tesirine as an intravenous (IV) infusion on Day 1 of each cycle, where 1 cycle is 3 weeks. Loncastuximab tesirine will be administered at a dose of 150 μg/kg for 2 cycles, then at a dose of 75 μg/kg for subsequent cycles.
Idelalisib	Idelalisib	Participants will be administered 150 mg idelalisib, orally, twice a day throughout each cycle, where 1 cycle is 4 weeks.

Primary Outcome Measures

Name	Time	Method
Complete Response Rate (CRR)	Up to the end of treatment, maximum time on treatment was 333 days	CRR was defined as the percentage of participants who experienced a best overall response (BOR) of complete response (CR) assessed prior to any subsequent anticancer treatment.

Secondary Outcome Measures

Name	Time	Method
Overall Response Rate (ORR)	Up to end of treatment, maximum time on treatment was 333 days	ORR was defined as the percentage of participants with a BOR of CR or partial response (PR) assessed prior to any subsequent anticancer treatment.
Duration of Response (DOR)	Up to end of treatment, maximum time on treatment was 333 days	DOR was defined as the time from the documentation of tumor response to disease progression or death.
Average Concentration of Loncastuximab Tesirine at the End of Infusion	Up to end of treatment, maximum time on treatment was 333 days
Overall Survival (OS)	Up to end of treatment, maximum time on treatment was 333 days	OS was defined as the time between the randomization date and death from any cause.
Average Concentration of Loncastuximab Tesirine Before Infusion	Up to end of treatment, maximum time on treatment was 333 days
Clearance Rate of Loncastuximab Tesirine	Up to end of treatment, maximum time on treatment was 333 days
Progression-Free Survival (PFS)	Up to end of treatment, maximum time on treatment was 333 days	PFS was defined as the time between the randomization date and the first documentation of recurrence, progression, or death.
Change From Baseline in Health-Related Quality of Life (HRQoL) as Measured by the EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)	Up to end of treatment, maximum time on treatment was 333 days
Volume of Distribution of Loncastuximab Tesirine	Up to end of treatment, maximum time on treatment was 333 days
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)	Day 1 to 30 days after end of treatment, maximum time on treatment was 333 days	TEAEs were defined as an AE that occurs or worsens in the period extending from the first dose of study treatment until 30 days after the last dose of study treatment or start of new anti-cancer therapy, whichever is earlier. Any clinically significant changes from baseline in the safety laboratory values, vital signs, 12-lead electrocardiogram (ECG), and Eastern Cooperative Oncology Group (ECOG) performance status were reported as TEAEs.
Number of Participants With Anti-Drug Antibody (ADA) Titers to Loncastuximab Tesirine	Up to end of treatment, maximum time on treatment was 333 days
Number of Participants With Specific Symptomatic Adverse Event Symptoms As Selected From Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)	Up to end of treatment, maximum time on treatment was 333 days	The specific symptomatic adverse events includes fatigue, swelling, rash, nausea, diarrhea, abdominal pain, and cough.
Treatment-Related Symptoms as Assessed by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)	Up to end of treatment, maximum time on treatment was 333 days	The specific symptoms assessed include fatigue, swelling, rash, nausea, diarrhea, abdominal pain, and cough. The severity is assessed from "None" to "Very severe" and the interference level is assessed from "Not at all" to "Very much."
Change From Baseline in Health-Related Quality of Life (HRQoL) as Measured by the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym)	Up to end of treatment, maximum time on treatment was 333 days

Trial Locations

Locations (34): Account University College London Hospitals NHS Foundation Trust
🇬🇧
London, United Kingdom
Hospital Universitario La Paz
🇪🇸
Madrid, Spain
Hospital Universitario Virgen del Rocío
🇪🇸
Sevilla, Spain
Hollings Cancer Center
🇺🇸
Charleston, South Carolina, United States
Universitair Ziekenhuis Gent
🇧🇪
Gent, Belgium
Soroka Medical Center
🇮🇱
Be'er Sheva, Israel
Summit Medical Group
🇺🇸
Florham Park, New Jersey, United States
Semmelweis Egyetem
🇭🇺
Budapest, Hungary
Centre Hospitalier de Dunkerque
🇫🇷
Dunkerque, France
Comprehensive Cancer Centers of Nevada
🇺🇸
Las Vegas, Nevada, United States
Hospital Universitario Ramón y Cajal
🇪🇸
Madrid, Spain
Hospital General Universitario Gregorio Marañón
🇪🇸
Madrid, Spain
Hospital Universitario Fundación Jiménez Díaz
🇪🇸
Madrid, Spain
Hospital Universitario Quirónsalud Madrid
🇪🇸
Pozuelo De Alarcón, Spain
Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)
🇪🇸
L'Hospitalet De Llobregat, Spain
Hospital Universitari Arnau de Vilanova
🇪🇸
Lleida, Spain
Centre Hospitalier de La Rochelle
🇫🇷
La Rochelle, France
Hôpital Bretonneau
🇫🇷
Tours Cedex 9, France
Azienda Ospedaliero - Universitaria Careggi
🇮🇹
Firenze, Italy
Centre de Lutte Contre le Cancer - Centre Henri-Becquerel
🇫🇷
Rouen, France
NHS Greater Glasgow and Clyde
🇬🇧
Glasgow, United Kingdom
Tel Aviv Sourasky Medical Center
🇮🇱
Tel Aviv, Israel
Pratia Onkologia Katowice
🇵🇱
Katowice, Poland
Summit Medical Group - Florham Park Campus
🇺🇸
Florham Park, New Jersey, United States
Inselspital Universitätsspital Bern
🇨🇭
Bern, Switzerland
Országos Onkológiai Intézet
🇭🇺
Budapest, Hungary
Pécsi Tudományegyetem Klinikai Központ
🇭🇺
Pécs, Hungary
Szpitale Pomorskie Spółka Z Ograniczoną Odpowiedzialnością
🇵🇱
Gdynia, Poland
Pratia Poznań
🇵🇱
Skorzewo, Poland
Comprehensive Cancer Centers of Nevada - Central Valley
🇺🇸
Las Vegas, Nevada, United States
Centre Hospitalier Universitaire Universite Catholique de Louvain
🇧🇪
Yvoir, Belgium
Carmel Medical Center
🇮🇱
Haifa, Israel
Rabin Medical Center - Beilinson Hospital
🇮🇱
Petah tikva, Israel
The Chaim Sheba Medical Center
🇮🇱
Tel Aviv, Israel